The Food and Drug Administration (FDA) announced on Thursday its first ever approval of a vaccine for the Ebola virus disease (EVD) meant for individuals age 18 and older.
The drug, called Ervebo was involved in a two-year study conducted during an Ebola outbreak in Guinea, which along with Sierra Leone and Liberia saw more than 11,000 deaths during that timeframe.
Ervebo vaccine has been proven 100% effective if administered minimum 10 days before exposure to the virus.
Ervebo is single-dosed injection and was used in 2018 by World Health Organization (WHO) in the Democratic Republic Congo (DRC) as an investigational vaccine to help combat the world’s second largest Ebola outbreak.
Ebola virus transmitted through direct contact with blood, body fluids and tissues of infected people or animals, as well as contact with surfaces and materials contaminated with the virus.
Ebola symptoms may appear as soon as two days or up to 21 days after exposure and can include fever, fatigue, muscles pain, headache and sore throat.
Leave a comment
0 Comments